GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Society of Hematology  (3)
  • 2000-2004  (3)
Material
Publisher
  • American Society of Hematology  (3)
Language
Years
  • 2000-2004  (3)
Year
Subjects(RVK)
  • 1
    In: Blood, American Society of Hematology, Vol. 104, No. 11 ( 2004-11-16), p. 2098-2098
    Abstract: Arsenic trioxide (ATO, Trisenox™) is currently being investigated as a potential drug to optimize imatinib based treatment of chronic myelogenous leukemia (CML). ATO has antileukemic activity against imatinib sensitive and resistant CML cell lines and primary cells derived from patients with CML. However, preliminary clinical data reveal only moderate activity of ATO in CML (imatinib sensitive or resistant). ATO-activity in acute myelogenous leukemia or multiple myeloma cells is inversely related to the intracellular Glutathione- (GSH-) content with cells bearing low GSH-levels being the most sensitive. To investigate whether this relationship plays a role in CML cell lines sensitive or resistant to the Bcr-Abl inhibitor imatinib, we determined the antiproliferative activity of ATO with regard to the cellular GSH-levels. Furthermore, we examined the ability of GSH-depletion as a therapeutic tool to sensitize CML cells to ATO. MTS-proliferation assays were performed to determine the concentration of ATO needed to induce 50% cellular growth inhibition (IC50). Cell lines used were the imatinib sensitive CML blast crisis lines AR230-s, KCL22-s, LAMA-s as well as their imatinib resistant derivatives AR230-r1, KCL22-r1, LAMA-r1. Known ATO-sensitive AML cell lines (NB4, HL60) with low GSH-content were also included in this study. Intracellular GSH-levels were measured biochemically using a commercially available kit. Protein content was analyzed using the Bradford method. ATO toxicity was analyzed using trypan blue exclusion and flow cytometric analysis of Annexin/PI-stained cells. MTS-proliferation assays indicate a cell type dependent activity of ATO with IC50-values ranging from 0.37±0.03 μM (NB4) up to 6.9±1.43 μM (AR230-r1). The most sensitive NB4 cells express low GSH-levels (8.74±2.9 nmol/mg), whereas highly resistant AR230-r1 cells reveal a threefold increased GSH-content (26.7±8nmol/mg). Imatinib resistance in AR230-r1 and LAMA-r1 cells is not associated with significant GSH-content modulation when compared to the imatinib naïve counterparts (23.6±5.4nmol/mg [AR230-s] vs 26.7±8nmol/mg [AR230-r1] ; 8.3±1.8nmol/mg [LAMA-s] vs 6.9±0.2 [LAMA-r1] ). Treatment of AR230-s cells with 100 μM of the GSH-depleting agent L-Buthionine-Sulfoximine (BSO) for 12 h leads to significant downregulation of cellular GSH (23.6±5.4 nmol/mg [control] vs 4,25±0,53 nmol/mg [100 μM BSO] ). Treatment with BSO alone does not affect cellular viability nor induces apoptosis. Subsequent cotreatment of AR230-s cells with ATO (1 μM) and BSO (100 μM) for 24 h reduces viability to 31.6 % compared to untreated cells. In contrast, treatment with 1 μM ATO alone does not affect viability. Flow cytometric analysis of apoptosis reflects viability data with a 5.5 fold increase of apoptotic cells in the combined treated fraction. Similar data were generated using the KCL22-s cell line. Experiments using primary patient cells are currently in progress. Our data indicate that high intracellular GSH-content confers relative resistance to ATO in Bcr-Abl positive cell lines regardless whether they are imatinib sensitive or resistant. A promising tool to increase the antileukemic activity of ATO is the application of GSH-depleting agents. Therefore, GSH-dependent response to ATO treatment needs further investigation in individual CML patients.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2004
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Blood, American Society of Hematology, Vol. 97, No. 11 ( 2001-06-01), p. 3648-3650
    Abstract: Recently, it was shown that interferon consensus sequence binding protein (ICSBP), a member of the interferon regulatory factor (IRF) family, has a potential role in chronic myeloid leukemia (CML). Deletion of ICSBP gene in mice leads to a CML-like syndrome and samples from CML patients exhibited impaired ICSBP expression. The present study found that ICSBP expression correlated with risk features determined by Sokal score in untreated CML (P = .007 for high versus low risk). In addition, analyzing ICSBP expression during interferon-α (IFN-α) therapy in “good” (n = 27) versus “poor” (n = 15) cytogenetic responders, high ICSBP levels were only observed in “good” responders (P = .0002). Together, these data suggest that ICSBP levels are related to initial presentation of CML and the therapeutic response of CML to IFN-α, indicating an important role of ICSBP in CML.
    Type of Medium: Online Resource
    ISSN: 1528-0020 , 0006-4971
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2001
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Blood, American Society of Hematology, Vol. 104, No. 11 ( 2004-11-16), p. 4763-4763
    Abstract: Background: Polycythemia vera (PV) is a chronic myeloproliferative disorder derived from multipotent hematopoetic precursors. The pathogenesis of PV is still poorly understood; furthermore, it is not clear, why the bone marrow (BM) of patients with PV has an increased microvessel density. Aims: For these reasons, we aimed to investigate, if BM angiogenesis and pathogenesis in PV are associated, and if the increased angiogenesis can elucidate pathophysiologic mechanisms of PV. Methods: BM biopsies were taken from patients with PV before and during treatment. A total of 38 samples from 35 patients were analyzed. In three patients, we investigated biopsies in 12 months intervals. Also, eight patients with iron deficiency were studied. BM angiogenesis in thin sections was determined by immunostaining of endothelial cells (CD34, vWF) and counting the microvessels. The microvessel counts were correlated to hematologic features such as treatment modalities and iron metabolism parameters (zinc protoporphyrin (ZPP), ferritin). Iron deficiency was classified to be mild for ZPP ≤ 100 micromol/mol hem (normal value & lt; 40) and for ferritin 7 to 35 microgramm/l (normal value & gt; 35), and to be severe for ZPP & gt; 100 micromol/mol hem and for ferritin & lt; 7 microgramm/l. Results: When compared to healthy controls, the number of BM microvessels in patients with iron deficient anemia was indistinguishable from healthy individuals. As expected, the BM microvessel numbers of patients with PV at diagnosis (n= 6) or with only mild iron deficiency treated with various therapy schedules (n=20) showed no significant difference (p=n. s.). In contrast, in patients with severe iron deficiency, we detected a highly significant difference between two different treatment modalities: phlebotomy alone was associated with a normal microvessel density (n=7; mean 3.6/mm2, range 2.7 to 5.7/mm2), whereas other treatment modalites or a combination with phlebotomy were associated with a high microvessel density (n=10; mean 10.4/mm2; range 4.5 to 15.7/mm2; p=0.0004). The microvessel counts of the patients from who two sequential biopsies were investigated are in line with these results: the microvessel numbers in a patient who received an oral iron treatment increased from 9.3 to 15/mm2; the microvessels of another patient who was treated with hydroxy urea and phlebotomy showed almost unchanged microvessel counts, whereas, in a third patient, who was treated exclusively by phlebotomy, a clear decrease of BM microvessel density from 15.7 to normal value of 4.5/mm2 was observed. Conclusions: We conclude that i) iron deficiency per se does not induce increased microvessel density in the BM, ii) a severe iron deficiency induced by phlebotomy alone can reduce the BM microvessel density in patients with PV to normal. Provided that the increased BM angiogenesis is associated with pathogenesis in PV, which means that the multipotent hematologic precursors account for the increased angiogenesis, efficient iron depletion by phlebotomy represents the highly potent treatment for PV.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2004
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...